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The T-cell immunoglobulin and mucin-3 (TIM-3)/galectin-9 (Gal-9) autocrine loop is an 
indispensable signaling in acute myeloid leukemia (AML) cells, which induces their self-renewal 
through activation of nuclear factor-kappa b (NF-kB) and β-catenin pathways. In this study, we 
evaluated the effects of oridonin and doxorubicin on the TIM-3/Gal-9 autocrine loop. We also 
evaluated oridonin anti-inflammatory and anti-cancer properties on U937 cells, as an AML cell 
line in comparison to doxorubicin as a common anthracycline drug for AML treatment. 
Cell counting kit-8 (CCK-8) was applied to evaluate the cytotoxicity of oridonin and 
doxorubicin on U937 cells and also to determine the impact of galectin-9 (Gal-9) on their 
proliferation. The effects of oridonin and doxorubicin on Gal-9, TIM-3, and interleukin-1β (IL-1β) 
gene expression were determined by real-time polymerase chain reaction (RT-PCR). The Gal-9 
secretion level was measured by enzyme-linked immunosorbent assay (ELISA) and activation of 
NF-kB pathway was assessed by western blotting. 
In a dose-dependent manner, oridonin and doxorubicin were capable to eradicate U937 cells 
while Gal-9 expanded them. Following the treatment of U937 cells with oridonin, the expression 
of Gal-9, TIM-3, and IL-1β genes was down-regulated, and the Gal-9 secretion and NF-kB 
phosphorylation were diminished, whereas doxorubicin increased all of these factors. 
Doxorubicin is a common treatment agent in AML, but it may induce inflammation and up-
regulate the TIM3/Gal-9 autocrine loop, consequently can enhance the possibility of disease 
relapse. Meanwhile, oridonin is capable to inhibit the essential signaling pathways in AML cells 
and reduce the inflammation and expansion of tumor cells and postpone AML recurrence. 
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INTRODUCTION 
 
Acute myeloid leukemia (AML) is a heterogeneous 
disorder of leukocytes in which, a clonal population of 
myeloid stem cells begins to grow and differentiate out 
of cellular autonomous controls. Thus, there will be lots 
of malignant cells in bone marrow, peripheral blood, 
and even other tissues. Meanwhile, AML is regarded as 
the most prevalent type of acute leukemia in adults 
with a poor prognosis.1 Development of AML mainly 
points out to some mutations in essential regulatory 
genes associated with cell proliferation and apoptosis 
such as fms-like tyrosine kinase 3 (FLT3), c-KIT, RAS, 
and p53 which might be considered as prognostic 
factors, too. Although targeting these genetic 
alterations could be beneficial in AML treatment, none 
of them were successful so far, due to the heterogeneity 
of these cells.1,2 
Currently, a combination of cytarabine and 
anthracyclines such as doxorubicin is applied as the main 
chemotherapy regime for the treatment of AML; 
however, the success rate of treatment in this regime is 
low and at least 50% of cases return with complete 
remission relapse.3,4 The reason for the low efficiency of 
current chemotherapy drugs might be due to the 
induction of inflammatory pathways in the tumor 
microenvironment. It seems that the activation of the 
nuclear factor kappa B (NF-κB) pathway and production 
of inflammatory cytokines such as interleukin (IL)-1, IL-
6, and tumor necrosis factor-alpha (TNF-α) may result in 
resistance of leukemic cells to chemotherapy and may 
boost the risk of relapse.5,6 
NF-κB inhibits cytochrome-c release by provoking 
B-cell lymphoma 2 (BCL-2) and X-linked inhibitor of 
apoptosis protein (XIAP) expression, as well as 
inducing the expression of TNF receptor-associated 
factor (TRAF)1, TRAF2, a cellular inhibitor of 
apoptosis protein (c-IAP)1, c-IAP2, and caspase-8 
inactivation as a result.7,8 NF-κB has a key role in the 
inflammatory responses and regulates lots of pro-
inflammatory genes. Its activation triggers the 
production of inflammatory cytokines (e.g. IL-1, IL-6, 
and TNF-α), chemokines (e.g. IL-8 and monocyte 
chemoattractant protein-1(MCP-1)), growth factors 
(e.g. vascular endothelial growth factor (VEGF) and 
granulocyte-macrophage colony-stimulating factor 
(GM-CSF)), matrix metalloproteinases (e.g. matrix 
metallopeptidases (MMP)2 and MMP9), and adhesion 
molecules (e.g. intercellular adhesion molecule 1 
(ICAM-1) and vascular cell adhesion molecule 
(VCAM)), which all of them promote tumor survival, 
metastasis, and chemotherapy-resistance.9 
In recent studies, T-cell immunoglobulin and 
mucin-3 (TIM-3) have been reported as a surface 
marker on leukemia stem cells in all AML phenotypes, 
except for M3, while normal hematopoietic stem cells 
do not express this molecule.10 It has been shown that 
there is an autocrine loop between TIM-3 and galectin-
9 (Gal-9) as one of its ligands in primary AML cells, 
which induces the self-renewal of AML cells through 
activation of NF-κB and β-catenin pathways. It was 
also shown that the neutralization of Gal-9 with a 
specific antibody can halt human AML reconstitution 
in immunodeficient mice.11 According to the mentioned 
observations, it seems that some of the chemotherapy 
drugs may induce downstream signaling pathways of 
the TIM-3/Gal-9 autocrine loop, which can potentially 
result in AML recurrence. 
Doxorubicin is an anthracycline chemotherapy drug 
that is used for the treatment of various cancers such as 
lung, breast, non-Hodgkin’s and Hodgkin’s lymphoma, 
multiple myeloma, and AML. Its mechanism is mainly 
based on inhibition of topoisomerase-II and production 
of free radicals which cause damage to different parts 
of cells and disrupt DNA repair.12 It is essential to 
mention that doxorubicin may induce inflammation by 
activation of p38 mitogen-activated protein kinases 
(MAPK) and NF-κB pathway. In addition, doxorubicin 
increases interleukin-1β (IL-1β) secretion through 
activation of the inflammasome and also induces the 
generation of other inflammatory factors such as TNF-
α, IL-6, granulocyte colony-stimulating factor (GCSF), 
C-x-C motif ligand (CXCL)10, CXCL1, C-C motif 
chemokine ligand 2 (CCL2).5,13 
Oridonin is a diterpenoid component with some 
unique characteristics, such as anti-bacterial and anti-
inflammatory properties. Moreover, this agent has 
some anti-tumor activities, which induces cell cycle 
arrest, apoptosis, and autophagy, as well as inhibiting 
the angiogenesis and migration of tumor cells. In 
addition, oridonin can hesitate the growth and 
expansion of cancer cells by generating reactive 
oxygen species (ROS) and regulation of telomerase 
activity.14-16 Oridonin inserts its anti-inflammatory 
properties by hindering the binding of NF-κB to 
chromosomal DNA and also inhibiting NF-κB entrance 
from the cytoplasm to the nucleolus by reducing the 
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expression of nucleoporins 88 and 214 on the nuclear 
membrane.17,18 Interestingly, the application of 
HAO472 as an oridonin derivative is under phase I of a 
clinical trial for AML treatment since 2015.14 
Based on the mentioned observations, we intended 
to evaluate the effects of oridonin and doxorubicin on 
the TIM-3/Gal-9 autocrine loop in the U937 cell line as 
a prototype of the AML cell line. In detail, we 
evaluated their effects on the expression of Gal-9, TIM-
3, and IL-1β genes, production of Gal-9, and also 
activation of the NF-κB pathway.  
 
MATERIALS AND METHODS 
 
Human AML Cell Line and Determination of Cell 
Viability  
All applied experiments were performed at the Iran 
University of Medical Science and the Research Ethics 
Committees approved the study proposal (Code # 
IR.IUMS.FMD.REC.1396.9411127008). 
The U937 cell line was obtained from Pasteur 
Institute (Tehran, Iran) and propagated in RPMI 1640 
medium containing 10% fetal bovine serum (FBS) and 
100 U/mL Penicillin and 100 µg/mL Streptomycin and 
maintained at 37˚C in a humidified 5% CO2 incubator. 
The cytotoxicity of various concentrations of oridonin 
(O9639, Sigma-Aldrich, Taufkirchen, Germany) and 
doxorubicin (A-4866, Unterach, Austria) on U937 cells 
was evaluated by Cell Counting Kit (CCK-8, Sigma-
Aldrich, Taufkirchen, Germany) according to the 
manual. We also treated U937 cells with Gal-9 and 
their proliferation level was determined with the  
CCK-8 kit. In this method, WST-8 [2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)- 
2H-tetrazolium, monosodium salt] is used to produce a 
water-soluble formazan dye upon bioreduction in the 
presence of 1-Methoxy PMS as an electron carrier. 
Approximately, 2×104 cells/well were seeded in a 96-
well plate and treated with 0-160 µM of oridonin, 0-
500 µM of doxorubicin, and 72-288 ng/mL of galectin-
9. After overnight incubation, 10 µL of CCK-8 solution 
was added to each well and the amount of formazan 
was measured by reading the absorbance at 460 nm 
which is directly proportional to the number of living 
cells. In the end, we selected three doses of oridonin 
and doxorubicin for the final experiments. 
 
Bioinformatics Study  
Pathway Studio was used as a Bioinformatics 
database to study the possible effects of oridonin and 
doxorubicin on the TIM-3/Gal-9 autocrine loop and to 
determine the related interactions. 
 
Real-time PCR 
Real-time PCR was used to determine the TIM-3 
(HAVCR2), Gal-9, and IL-1β mRNA levels. 
Approximately, 3×106 cells/well were seeded in 6-well 
plates, treated with selected doses of oridonin, 
doxorubicin, and lipopolysaccharide (L2262, Sigma-
Aldrich, Taufkirchen, Germany), and incubated 
overnight. After 24 h, cell supernatant was removed and 
total RNA was extracted; using TRIZOL reagent (DNA 
biotech, Tehran, Iran) through guanidinium thiocyanate-
phenol-chloroform extraction method and applied for 
cDNA synthesis; using a commercial kit (Thermo 
Scientific, Massachusetts, USA). Finally, the expression 
level of target genes was evaluated by real-time PCR; 
using specific primers (Table 1) and SYBR Green I 
MasterMix (Takara, Shiga, Japan) and the results were 
normalized; using GAPDH as the house-keeping gene. 
 
Table 1. The details of primers used in real-time PCR 
Gene Name Primer Sequences (5′ to 3′) Primer Length (bps) 
Amplified Fragment 
Length (bps) 
Galectin-9 F-GATGAGAATGCTGTGGTCCG 20 260 
R- GAAGCCGCCTATGTCTGCA 19 
TIM-3 (HAVCR2) F- TCTTCCCTTTGACTGTGTCCT 21 175 
R- TTCAAACACAGGACAGGCTC 20 
IL-1β F- AGCTTGGTGATGTCTGGTCC 20 167 
R- ACGCAGGACAGGTACAGATT 20 
GAPDH F- GCACCGTCAAGGCTGAGAAC 20 138 
R- TGGTGAAGACGCCAGTGGA 19 
F: Forward primer, R: Reverse primer, TIM-3: T-cell immunoglobulin and mucin-domain containing-3, IL-1β: Interleukin 1-Beta. 
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Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA was carried out to measure the amount of 
Gal-9 secretion from U937 cells to the tissue culture 
medium. Approximately, 3×106 cells/mL seeded in 6-
well tissue culture plates and treated with selected 
doses of oridonin and doxorubicin. After 24 h 
incubation, the cell culture supernatant was harvested 
and used to measure human Gal-9; using a commercial 




For assessment of total NF-κB and its 
phosphorylated form, the treated cells were lysed and 
applied for immunoblotting. In brief, 3×106 cells/mL 
were seeded in 6-well plates and treated with oridonin 
and doxorubicin. After 24 h incubation, cells were 
harvested and washed with cold PBS and lysed using 
RIPA buffer (Santa Cruz, Texas, USA) containing 
phosphatase and protease inhibitors within 15 minutes 
on ice. The lysate underwent centrifugation at 10,000 g 
for 15 min at 4˚C. Protein concentration was 
determined by the Bicinchoninic acid (BCA) protein 
assay kit (Parstous, Mashad, Iran). The ingredients 
were resolved on 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and 
the separated proteins were electrotransferred on 
polyvinylidene difluoride (PVDF) membrane. The 
membrane was rinsed with Tris-buffered saline 
containing 0.05% Tween 20 (TBST) and blocked by 
5% skimmed milk and incubated with optimized 
concentrations of primary mouse monoclonal 
antibodies against NF-κB p65 and phospho-NF-κB p65 
(sc-514451 and sc-136548, Santa Cruz, Texas, USA) in 
parallel with rabbit anti-beta actin antibody (ab8227, 
Abcam, Cambridge, UK). After an extensive wash 
(three times, each 5 min) with TBST, the membrane 
was incubated with horseradish peroxidase (HRP)-
conjugated polyclonal antibodies against rabbit IgG or 
mouse IgG for 1 h. After another extensive washing, 
the immunoblots were visualized using 




The statistical analysis was performed using 
STATA/SE version 12.0 software (STATA Corp, TX, 
USA) and the data were presented by GraphPad Prism 
version 7 (San Diego, CA, USA). First of all, using the 
Kolmogorov-Smirnov test, the normal distribution of 
the variables was evaluated. Then the continuous 
variables were expressed as mean±standard deviation 
(SD) and were compared among more than two 
independent groups by One-way ANOVA and 
Bonferroni. At the protein level, we performed 
nonparametric tests. Kruskal–Wallis, and Dunn tests 
were performed to compare between more than two 
independent groups. Moreover, Benjamini–Hochberg 
was done to control the false discovery rate (FDR) in 




The Effect of Oridonin and Doxorubicin on 
Signaling Pathways 
Bioinformatics analysis by Pathway Studio showed 
that oridonin may block NF-κB, β-catenin, and WNT 
signaling pathways, hence, it might be capable to 
reduce the expansion of AML cells by disrupting this 
vital loop (Figure 1) while doxorubicin acts oppositely. 
 
Cytotoxicity of Doxorubicin and Oridonin on U937 
Cells 
CCK-8 test showed that both oridonin and 
doxorubicin are capable to eliminate tumor cells in a 
dose-dependent manner. In this regard, the IC-50 
concentration of oridonin and doxorubicin was 
estimated at 127 µM and 370 nM, respectively. 
Therefore, three non-cytotoxic levels, including 20, 40, 
and 80 µM for oridonin and 40, 80, and 160 nM for 
doxorubicin were selected for final experiments (Figure 
2A and B). 
 
The Effect of Gal-9 on Proliferation of U937 Cells 
The effect of galectin-9 on U937 cells was 
evaluated by the CCK-8 test. The results showed that 
galectin-9 can enhance the proliferation of U937 cells 
in a dose-dependent manner (Figure 2C).  
 
The Effect of Doxorubicin and Oridonin on IL-1β, 
TIM-3, and Gal-9 Gene Expression 
Real-time PCR showed that oridonin significantly 
down-regulates IL-1β gene expression in the U937 cell 
line. In addition, 20-40 µM doses of oridonin could 
diminish TIM-3 (HAVCR2) and Gal-9 gene 
expression, too (Figure 3A, B, and C). In contrast, 
doxorubicin increased the expression of the mentioned 
gens.  
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Figure 1. Evaluation of the effects of oridonin and doxorubicin on 
autocrine loop: As it is shown oridonin in contrast to doxorubicin may interrupt this loop by inactivating β
and nuclear factor-kappa b (NF-κB) signaling.
Figure 2. The effect of various concentrations of oridonin and doxorubicin
on the viability of U937 cells after 24 hours. A
independent experiments, each performed in triplicate. 
kit (CCK) assay, pointing out to viable cells. Statistical analysis was performed on the percentage of viability, using On
ANOVA and Bonferroni. Data represent mean
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T-cell immunoglobulin mucin-3 
 
 for evaluation of IC 50 (A, B) and Galectin
-B: Data represents the mean (± SD) of viability percentage obtained 
C: Data represents the optical density (OD) obtained 
 ± SD. (*p < 0.05, ***p < 0.001).  







in cell counting 
e-way 
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The Effect of Doxorubicin and Oridonin on Gal-9 
Secretion  
In the presence of LPS as an inflammation-inducing 
agent, Gal-9 secretion was increased and when LPS 
was used in combination with doxorubicin, the 
secretion of Gal-9 was increased significantly, while 
oridonin as an anti-inflammatory agent did not increase 
Gal-9 secretion in low doses (e.g. 20 µM) (Figure 3D).  
 
The Effect of Doxorubicin and Oridonin on NF-κb 
Expression 
Western blotting showed that oridonin not only 
down-regulated total NF-κB but also reduced its 
phosphorylated form and the reduction of the activated 
form was more significant. While doxorubicin 
increased the phosphorylated form of NF-κB but did 




Figure 3. The effect of various concentrations of oridonin and doxorubicin in presence of lipopolysaccharides (LPS) on the 
gene expression of T-cell immunoglobulin mucin-3 (TIM-3), galectin-9, and IL-1β and the secretion of galectin-9 after 24 
hours. A-C: Data represents the mean (± SD) of fold changes from two independent experiments, each performed in 
triplicate. Statistical analysis was performed on Log2 fold change, using One-way ANOVA and Bonferroni. Error bars 
indicate ± SD. (*p<0.05). D: Data represents the mean (± SD) concentration of Galactin-9 secreted following treatment with 
LPS and the studied medications in two independent experiments, each performed in duplicate. Statistical analysis was 
performed on the optical density, using One-way ANOVA and Bonferroni. Data represent mean ± SD. (***p < 0.001). 
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Figure 4. The effect of oridonin and doxorubicin in the presence of lipopolysaccharides on nuclear factor-kappa b (NF-κB) 
expression: The effect of A) oridonin at concentrations of 20 µM and 40 µM as well as B) doxorubicin at concentrations of 80 
nΜ and 160 nΜ in the presence of lipopolysaccharides (LPS) on the protein level of NF-κB and phospho-nuclear factor-
kappa b (p-NF-κB) in U937 cell line after 24 h treatment was measured. Statistical analysis was performed on normalized 
protein expression with β-actin from one experiment, performed in triplicate, using Kruskal–Wallis, Dunn test, Benjamini–




AML is one of the deadliest leukemias which up to 
now no efficient therapy has been developed against it. 
About 50% of the patients experience recurrence after 
receiving chemotherapy drugs as a main therapeutic 
approach. Epidemiologic studies show that AML has a 
higher incidence in older individuals. Meanwhile, we 
are aware that more inflammatory mediators are 
produced in elderly people than youngsters; thus it 
seems that there might be a linkage between 
inflammation and incidence of AML recurrence.19 One 
of the main molecular alterations along with aging is 
the enhancement of NF-κB signaling which gradually 
results in overexpression of multiple inflammatory 
genes and augmentation of different inflammatory 
mediators.20 In brief, NF-κB is an important 
transcription factor that regulates various aspects of 
innate and adaptive immunity and is regarded as a key 
mediator of inflammation.21Furthermore, another facet 
of NF-κB activation could be cancer progression. In 
this context, some studies show that activation of this 
transcription factor promotes cancer progression by 
inhibiting the apoptosis of cancer cells as well as 
inducing angiogenesis and metastasis.22 A recent study 
showed that NF-κB is also involved in TIM-3/Gal-9 
signaling and might be capable to increase the survival 
rate of AML cells.11 Therefore, NF-κB inhibition may 
be effective in TIM-3/Gal-9 autocrine loop 
suppression. In this study, we showed that oridonin 
down-regulated the total amount of NF-kB and its 
phosphorylation rate after treatment, meanwhile, 
doxorubicin increased its phosphorylation rate but the 
total amount remained stable. Reduction of the active 
or phosphorylated form of NF-κB following oridonin 
treatment revealed that it has an inhibitory effect on 
this pathway and not only may diminish inflammation 
but also could impede AML progress in the opposite to 
doxorubicin. 
One of the most important inflammatory cytokines 
which are regulated by NF-κB is IL-1β which is 
regarded as a major regulatory molecule in 
inflammation, innate immunity, and hematopoiesis. 
Moreover, it is an effective cytokine in various steps of 
cancer development including its initiation, 
angiogenesis, and metastasis. For instance, it may 
induce DNA alteration through promoting the synthesis 
of reactive oxygen intermediates and nitrogen active 
species in phagocytic cells which can pave the way for 
the onset of cancer in some conditions. It also promotes 
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the production of angiogenic factors such as IL-8, 
VEGF, hepatocyte growth factor (HGF), and fibroblast 
growth factor (FGF) and also enhances the production 
of elements involved in metastasis of the tumor cells 
such as MMPs, IL-6, TNF-α, transforming growth 
factor-beta (TGF-ß).23,24 
Previous studies suggest an important function for 
IL-1β in AML. Carey et al, through the blocking of the 
P38MAPK signaling, could indirectly suppress the IL-
1β pathway and inhibited the expansion of AML 
cells.25 Of course, IL-1β, through P38MAPK-
dependent mechanisms, may enhance the activity of the 
GATA2 transcription factor which is a key regulator 
for a set of inflammatory genes that influence the 
progression of AML.25 In addition, IL-1β stimulates the 
generation of growth factors such as stem cell factor 
(SCF), which have a significant effect on the spreading 
of the disease.26 By considering the mentioned 
concepts, we intended to assess the expression level of 
this cytokine following oridonin and doxorubicin 
treatment. The experiments showed that oridonin 
decreases the expression level of IL-1β and 
consequently reduced inflammation in contrast to 
doxorubicin. Surely, evaluation of IL-1β secretion by 
immunoassay methods may provide further 
confirmatory hints. 
Gal-9 is another fundamental molecule in AML 
promotion which is secreted in large amounts by these 
cells and is beneficial in tumor cells’ invasion through 
suppressing the cytotoxicity of NK cells and decreasing 
IL-2 secretion by CTLs.27 Initially, it was considered as 
an eosinophil chemoattractant factor, but gradually 
more functions such as provoking inflammation by 
monocytes and dendritic cells were discovered for it. It 
causes apoptosis in T helper-1 (TH1) and T helper-17 
(TH17) cells and increases T regulatory response 
following ligation to its receptor named TIM-3 which 
means that Gal-9 has the opposite role.28 
A recent study showed that Gal-9 and its receptor 
on AML leukemia stem cells comprise an 
indispensable autocrine loop that leads to the activation 
of diverse signaling pathways being useful in the 
survival and expansion of AML cells. So we evaluated 
the impacts of oridonin and doxorubicin on the 
production of these two pivotal molecules to make sure 
if there are any possible inhibitory effects. To examine 
our hypothesis, first, we evaluated Gal-9 effects on the 
proliferation of AML cells by CCK-8 and the results 
showed Gal-9 could induce proliferation of the cells. 
Previously, Kikushige et al showed that the TIM-3/Gal-
9 autocrine loop has a key role in the expansion of 
AML cells. Thus, targeting the Gal-9 or TIM-3/Gal-9 
autocrine loop could be a suitable candidate to inhibit 
the expansion of AML cells, along with the 
chemotherapy regime. 
As mentioned before, oridonin and doxorubicin are 
capable of eradicating tumor cells; using cell cycle 
arrest and inducing apoptosis or autophagy. To check 
oridonin and doxorubicin cytotoxicity, we treated U937 
cells with various doses of these chemicals, and their 
127 µm and 370 nΜ concentration were determined as 
IC50 respectively, finally, three doses with less than 
30% cytotoxicity were chosen for further studies. Our 
results showed that oridonin not only annihilate cancer 
cells but also decreased TIM-3 expression, thus, it may 
halt AML recurrence. But doxorubicin enhanced TIM-
3 expression. Surely, the determination of TIM-3 
protein alteration by flow cytometry or western blotting 
in future studies could provide more helpful hints. 
Furthermore, we assessed oridonin and doxorubicin 
effects on Gal-9 secretion and found that oridonin 
reduces Gal-9 expression levels as compared to 
doxorubicin. As mentioned before, Gal-9 can stimulate 
the proliferation of AML cells and repress immunity 
against tumors by promoting apoptosis in 
immunocompetent cells such as TH1 cells. 
In this in vitro study, we showed that oridonin can 
reduce Gal-9 and TIM-3 expression which may disturb 
the TIM-3/Gal-9 loop while doxorubicin increased 
these molecules. Hence we concluded that not only 
oridonin can prevent the proliferation of AML cells but 
also it may avoid the relapse of the disease. Although 
doxorubicin can eradicate tumor cells, it may induce 
cancer relapse by increasing TIM-3/Gal-9 signaling. 
Surely, these finding should be implemented for AML 
cells derived from the patients and finally confirmed in 
a randomized controlled trial. 
In conclusion, it seems that the TIM-3/Gal-9 
autocrine loop can be an important mechanism for 
AML recurrence, thus its targeting could be helpful in 
AML treatment. Moreover, it should be considered that 
some chemotherapy drugs can induce inflammation and 
augment vital molecules including TIM-3 and Gal-9. 
Thus it seems that the application of an anti-
inflammatory component besides the chemotherapy 
drugs or substituting them with chemotherapy 
medication with anti-inflammatory properties may 
result in more successful treatment in AML patients. 
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